Farxiga (dapagliflozin) is an orally administered, brand-name medication classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor. SGLT2 inhibitors help lower blood sugar by causing the ...

Farxiga (dapagliflozin) and Jardiance (empagliflozin) are prescription medications that are commonly used for type 2 diabetes ...

AstraZeneca’s Farxiga has become the latest type 2 diabetes drug to show it can reduce cardiovascular risk in a clinical trial. Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin ...

Farxiga (dapagliflozin) may not be safe to take while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine whether you ...

AstraZeneca has scored a major trial victory after its Farxiga (dapagliflozin) became the first drug in its class to show efficacy in heart failure, in patients with or without type-2 diabetes.

Medicare Part D spending for 10 selected diabetes drugs surged from $7.7 billion in 2019 to $35.8 billion in 2023, an audit ...